WO2024063661A1 - A pharmaceutical composition for topical application and use thereof in the treatment of hemangiomas in children - Google Patents

A pharmaceutical composition for topical application and use thereof in the treatment of hemangiomas in children Download PDF

Info

Publication number
WO2024063661A1
WO2024063661A1 PCT/PL2023/050078 PL2023050078W WO2024063661A1 WO 2024063661 A1 WO2024063661 A1 WO 2024063661A1 PL 2023050078 W PL2023050078 W PL 2023050078W WO 2024063661 A1 WO2024063661 A1 WO 2024063661A1
Authority
WO
WIPO (PCT)
Prior art keywords
triamcinolone
composition
hemangiomas
children
pharmaceutical composition
Prior art date
Application number
PCT/PL2023/050078
Other languages
French (fr)
Inventor
Jerzy Niedzielski
Paweł Szymański
Kamila Czarnecka
Original Assignee
Universytet Medyczny W Łodzi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universytet Medyczny W Łodzi filed Critical Universytet Medyczny W Łodzi
Publication of WO2024063661A1 publication Critical patent/WO2024063661A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the subj ect matter of the invention is a pharmaceutical composition for topical application containing a beta- adrenergic receptor antagonist and a corticosteroid and use thereof in the treatment of hemangiomas in children .
  • Hemangiomas are the most common mild tumors of early childhood that occur in children with an incidence of between 4 and 10 % .
  • Early childhood angiomas develop on the face and neck ( approx . 80 % of cases ) as well as on the trunk and limbs .
  • a phase of rapid proli ferative growth of angiomas starts which extends until the end of the child' s first year of age .
  • the subsequent phase of slow regression di f fers in its duration and may extend until the age of 5-10 years . Approx . 10-15 % of early childhood angiomas grow to si zes that cause functional impairment of an organ or are li fe-threatening to the child .
  • topical therapy has started to be used through the superficial application of medicines in the form of cream, gel or ointment on angiomas (1, 3, 4) .
  • medicines in the form of cream, gel or ointment on angiomas (1, 3, 4) .
  • ophthalmic drops timolol
  • oral tablets or intravenous injections (propranolol) (3) , that is, medicines that according to manufacturers' instructions should be applied via different routes.
  • intralesional therapies are known, which involve an injection of a formulation inside a lesion; the therapy, however, requires general anesthesia and, therefore, hospitalization and involvement of specialized staff, with a potential risk of local and systemic complications.
  • the objective of the invention was to develop a pharmaceutical composition for topical application effective in the treatment of hemangiomas in children.
  • the subj ect matter of the invention is a pharmaceutical composition for topical application, characteri zed in that it contains a beta-adrenergic receptor antagonist , a corticosteroid and a pharmaceutically acceptable carrier, wherein the beta-adrenergic receptor antagonist is labetalol or a pharmaceutically acceptable salt thereof , and the corticosteroid is selected from a group including triamcinolone , triamcinolone acetonide , triamcinolone hexacetonide and triamcinolone diacetate .
  • the pharmaceutically acceptable salt of labetalol is the hydrochloride .
  • the weight ratio of the beta-adrenergic receptor antagonist to the corticosteroid is 1 : 3 .
  • the concentration of the beta-adrenergic receptor antagonist in the composition is 0 . 02-0 . 5 % by weight .
  • the concentration of the corticosteroid in the composition is 0 . 02-0 . 5 % by weight .
  • the composition is in the form of cream, ointment or gel .
  • Another subj ect matter of the invention is a pharmaceutical composition as defined before for use in the treatment of hemangiomas in children .
  • An advantage of the invention is that one formulation is used instead of several formulations .
  • Two substances from two distinct therapeutic groups a beta-adrenergic receptor antagonist and a corticosteroid
  • a beta-adrenergic receptor antagonist and a corticosteroid are combined in one formulation . Therefore , concomitant use of several formulations , whose combined ef fects ( antagonism, synergy) are unknown, is avoided .
  • This is not only convenient but first of all safe , both for the child (patient) and for the person who applies the formulations (errors may occur when several formulations are used; the dose as required is ensured) .
  • Another advantage of the invention is that the formulation is used externally. Even though most angiomas are located within the skin, previous therapeutic methods were based on the administration of formulations by mouth or in the form of injections, thus having systemic effects on the body; this involves a need for general anesthesia, hospitalization and hiring specialized personnel in small children.
  • the pharmaceutical composition of the invention is used topically, that is, only in the affected site, which definitely reduces the systemic effects of medicines administered. Therefore, the risk of undesirable effects due to the medicines administered, and thus their adverse effect on the child's health, is minimized.
  • the solution as developed facilitates the application of the formulation at home by the family. Hospitalization or involvement of medical professionals is not required, which is convenient for parents and children.
  • Another advantage of the invention is a reduced dosage of medicines administered.
  • the efficacy of any therapy depends on the administration of required drug doses.
  • beta-adrenergic receptor antagonists (betablockers) administered by mouth have systemic effects, first of all on the cardiovascular system when used as indicated. After achieving the required therapeutic level in the patient's blood, they act by saturating all tissues and organs with the therapeutic substance. Vascular lesions in the skin are not the principal therapeutic target of betablockers, and a side effect is rather involved.
  • drug doses administered topically can be reduced, because there is no need for loading the patient ' s whole body to achieve a drug concentration so that it can penetrate the lesion ( from inside ) .
  • the pharmaceutical composition of the invention acts directly on the lesion .
  • the doses could be reduced to increase the strength of action compared to conventionally used concentrations of the drugs administered separately : additive synergy was achieved .
  • an angioma cell line was used : EOMA (ATCC® CRL-2586TM) Hemangioendothel ioma .
  • the cells were grown in the EMEM (ATCC ) medium and seeded in a 96-well plate for 24 hours . Subsequently, they were incubated with the test compound in selected concentrations : 50-350 pM (the compound was dissolved in DMSO and water ) for 48 hours . The final methanol concentration in each well was 1 pL per 100 pL of the medium .
  • the EMEM medium with 1 pL methanol added was used as control and pure methanol was the positive control .
  • a cytotoxicity test was performed after 48 h of incubation according to the Vybrant MTT cell proli feration test kit : 10 pL of 12 mM MTT stock solution was added to the cells and further incubated at 37 ° C for 4 h . Volume of 25 pL was removed from the wells after incubation and 50 pL DMSO was added . The plates were incubated at 37 ° C for 10 min and absorbance at 540 nm was read .
  • test compounds were four compounds acting on beta-adrenergic receptors : propranolol hydrochloride , labetalol hydrochloride , atenolol and isoprenaline hydrochloride, and four corticosteroids: prednisolone, prednisone, hydrocortisone, and triamcinolone.
  • IC50 values for all eight test compounds were determined as a result of tests in cell lines. The lowest IC50 values were found for labetalol hydrochloride and triamcinolone. These were 308 pM and 844 pM, respectively.
  • EOMA ATCC® CRL-2586TM
  • Hemangioendothelioma Hemangioendothelioma
  • a stock solution (S2) of triamcinolone with a concentration of 1 688.5 pM was prepared.
  • a stock solution (SI) of labetalol hydrochloride with a concentration of 617.8 pM was prepared.
  • the assumption was to prepare a combination of concentrations within the IC50 values determined in cell lines for the test compounds in stage one of the studies. Table 1 below shows how combinations of concentrations were prepared to determine the best synergic action of both substances.
  • angioma cell line was used : EOMA (ATCC® CRL-2586TM) Hemangioendothel ioma .
  • the cells were grown in the EMEM (ATCC ) medium and seeded in a 96-well plate for 24 hours . Subsequently, they were incubated with the test compound in selected concentrations as listed in Table 1 for 48 hours . The final methanol concentration in each well was 1 pL per 100 pL of the medium .
  • the EMEM medium with 1 pL methanol added was used as control and pure methanol was the positive control .
  • a cytotoxicity test was performed after 48 h of incubation according to the Vybrant MTT cell proli feration test kit : 10 pL of 12 mM MTT stock solution was added to the cells and further incubated at 37 ° C for 4 h . Volume of 25 pL was removed from the wells after incubation and 50 pL DMSO was added . The plates were incubated at 37 ° C for 10 min and absorbance at 540 nm was read .
  • Cream was prepared .
  • Cream was prepared .
  • Cream was prepared .
  • Ointment was prepared.
  • Ointment was prepared.
  • micronized substances are dissolved in the solution.
  • the weighed gel bases were ground in a mortar, and a solution containing labetalol hydrochloride and triamcinolone was gradually added. The grinding was continued until a homogenous mass was obtained.
  • Peng Xu et al. "A self-controlled study of intralesional injection of diprospan combined with topical timolol cream for treatment of thick superficial infantile hemangiomas”; Dermatologic Therapy 2018, 31, el2595; DOI: 10.1111/dth.12595;

Abstract

The subject matter of the invention is a pharmaceutical composition for topical application containing a beta- adrenergic receptor antagonist and a corticosteroid and use thereof in the treatment of hemangiomas in children.

Description

A pharmaceutical composition for topical application and use thereof in the treatment of hemangiomas in children
Description
Technical Field
The subj ect matter of the invention is a pharmaceutical composition for topical application containing a beta- adrenergic receptor antagonist and a corticosteroid and use thereof in the treatment of hemangiomas in children .
Background Art
Hemangiomas are the most common mild tumors of early childhood that occur in children with an incidence of between 4 and 10 % . Early childhood angiomas develop on the face and neck ( approx . 80 % of cases ) as well as on the trunk and limbs . As early as in the first weeks of li fe , a phase of rapid proli ferative growth of angiomas starts which extends until the end of the child' s first year of age . The subsequent phase of slow regression di f fers in its duration and may extend until the age of 5-10 years . Approx . 10-15 % of early childhood angiomas grow to si zes that cause functional impairment of an organ or are li fe-threatening to the child . Systemic therapy and/or surgical treatment need to be started immediately in such patients . Several therapeutic modalities are available for the other cases of angiomas : laser therapy, scleroti zation, cryotherapy, surgical excision, which require the patient to undergo general anesthesia . Another approach is the oral administration of cardiac medicines (propranolol ) ( 2 ) which accelerate the regression of vascular lesions , frequently all the way to their complete disappearance . Their ef fect on angiomas was revealed by accident ; nevertheless , they are currently routinely used worldwide based on accepted standards owing to their high efficacy. An inconvenient aspect of the therapy is the need for initial hospitalization (2-3 days) , an ECG to be performed and a cardiology consultation to evaluate the patient's eligibility for therapy .
To eliminate these disadvantages, topical therapy has started to be used through the superficial application of medicines in the form of cream, gel or ointment on angiomas (1, 3, 4) . These are formulated on demand based on commercially available ready-made products, such as ophthalmic drops (timolol) (4) , oral tablets or intravenous injections (propranolol) (3) , that is, medicines that according to manufacturers' instructions should be applied via different routes. In addition, intralesional therapies are known, which involve an injection of a formulation inside a lesion; the therapy, however, requires general anesthesia and, therefore, hospitalization and involvement of specialized staff, with a potential risk of local and systemic complications.
The efficacy of any medicines administered was not tested in any of the therapeutic modalities previously used in practice, including those listed above, and their therapeutic doses considering the different application method or synergy of action, in particular combinations with corticosteroids, were not determined.
A publication of Peng Xu et al. : "A self-controlled study of intralesional injection of diprospan combined with topical timolol cream for treatment of thick superficial infantile hemangiomas"; Dermatologic Therapy 2018, 31, el2595; DOI: 10 .1111/dth .12595 disclosed a combination therapy of hemangiomas in children which involved an intralesional injection of diprospan and topical application of cream containing 0.5 % timolol.
A publication of Alahmady H. Alsmman et al. : "Combined oral propranolol with intralesional injection of triamcinolone acetonide in treatment of infantile periocular hemangiomas"; Clinical Ophthalmology 2017, 11, 2177-2181; http://dx.doi.org/10.2147/OPTH.S153121 disclosed a combination therapy of hemangiomas in children which involved oral administration of propranolol and intralesional injection of triamcinolone acetonide.
A publication of Wenhu Zhou et al. : "Formulation, characterization and clinical evaluation of propranolol hydrochloride gel for transdermal treatment of superficial infantile hemangioma"; Drug Development and Industrial Pharmacy 2014, Informa Healthcare USA, Inc.; DOI: 10.3109/03639045.2014.931968 disclosed a manufacturing process for a pharmaceutical composition in the form of gel, containing propranolol hydrochloride, HPMC, a terpene, alcohol and other excipients for treating hemangiomas in children .
A publication of Retno Danarti et al. Topical Timolol Maleate 0.5 % for Infantile Hemangioma: Its Effectiveness Compared to Ultrapotent Topical Corticosteroids - A SingleCenter Experience of 278 Cases. Dermatology 2016; 232: 566- 571 disclosed a comparison of the efficacy of steroid ointment with ointment containing timolol.
Summary of Invention
The objective of the invention was to develop a pharmaceutical composition for topical application effective in the treatment of hemangiomas in children. The subj ect matter of the invention is a pharmaceutical composition for topical application, characteri zed in that it contains a beta-adrenergic receptor antagonist , a corticosteroid and a pharmaceutically acceptable carrier, wherein the beta-adrenergic receptor antagonist is labetalol or a pharmaceutically acceptable salt thereof , and the corticosteroid is selected from a group including triamcinolone , triamcinolone acetonide , triamcinolone hexacetonide and triamcinolone diacetate .
Preferably, the pharmaceutically acceptable salt of labetalol is the hydrochloride .
Preferably, the weight ratio of the beta-adrenergic receptor antagonist to the corticosteroid is 1 : 3 .
Preferably, the concentration of the beta-adrenergic receptor antagonist in the composition is 0 . 02-0 . 5 % by weight .
Preferably, the concentration of the corticosteroid in the composition is 0 . 02-0 . 5 % by weight .
Preferably, the composition is in the form of cream, ointment or gel .
Another subj ect matter of the invention is a pharmaceutical composition as defined before for use in the treatment of hemangiomas in children .
An advantage of the invention is that one formulation is used instead of several formulations . Two substances from two distinct therapeutic groups ( a beta-adrenergic receptor antagonist and a corticosteroid) , previous ly used separately, are combined in one formulation . Therefore , concomitant use of several formulations , whose combined ef fects ( antagonism, synergy) are unknown, is avoided . This is not only convenient but first of all safe , both for the child (patient) and for the person who applies the formulations (errors may occur when several formulations are used; the dose as required is ensured) .
Another advantage of the invention is that the formulation is used externally. Even though most angiomas are located within the skin, previous therapeutic methods were based on the administration of formulations by mouth or in the form of injections, thus having systemic effects on the body; this involves a need for general anesthesia, hospitalization and hiring specialized personnel in small children. The pharmaceutical composition of the invention is used topically, that is, only in the affected site, which definitely reduces the systemic effects of medicines administered. Therefore, the risk of undesirable effects due to the medicines administered, and thus their adverse effect on the child's health, is minimized. The solution as developed facilitates the application of the formulation at home by the family. Hospitalization or involvement of medical professionals is not required, which is convenient for parents and children.
Another advantage of the invention is a reduced dosage of medicines administered. The efficacy of any therapy depends on the administration of required drug doses. For example, beta-adrenergic receptor antagonists (betablockers) administered by mouth have systemic effects, first of all on the cardiovascular system when used as indicated. After achieving the required therapeutic level in the patient's blood, they act by saturating all tissues and organs with the therapeutic substance. Vascular lesions in the skin are not the principal therapeutic target of betablockers, and a side effect is rather involved. Owing to the pharmaceutical composition of the invention, drug doses administered topically ( externally) can be reduced, because there is no need for loading the patient ' s whole body to achieve a drug concentration so that it can penetrate the lesion ( from inside ) . When administered topically, the pharmaceutical composition of the invention acts directly on the lesion . In addition, based on the results of in vitro studies into the synergy of medicines combined in appropriate concentrations ( the corticosteroid and the beta-blocker ) , the doses could be reduced to increase the strength of action compared to conventionally used concentrations of the drugs administered separately : additive synergy was achieved .
Examples
Example 1
Determination of IC50 for selected compounds
In the experiment , an angioma cell line was used : EOMA (ATCC® CRL-2586™) Hemangioendothel ioma . The cells were grown in the EMEM (ATCC ) medium and seeded in a 96-well plate for 24 hours . Subsequently, they were incubated with the test compound in selected concentrations : 50-350 pM ( the compound was dissolved in DMSO and water ) for 48 hours . The final methanol concentration in each well was 1 pL per 100 pL of the medium . The EMEM medium with 1 pL methanol added was used as control and pure methanol was the positive control . A cytotoxicity test was performed after 48 h of incubation according to the Vybrant MTT cell proli feration test kit : 10 pL of 12 mM MTT stock solution was added to the cells and further incubated at 37 ° C for 4 h . Volume of 25 pL was removed from the wells after incubation and 50 pL DMSO was added . The plates were incubated at 37 ° C for 10 min and absorbance at 540 nm was read . The test compounds were four compounds acting on beta-adrenergic receptors : propranolol hydrochloride , labetalol hydrochloride , atenolol and isoprenaline hydrochloride, and four corticosteroids: prednisolone, prednisone, hydrocortisone, and triamcinolone.
IC50 values for all eight test compounds were determined as a result of tests in cell lines. The lowest IC50 values were found for labetalol hydrochloride and triamcinolone. These were 308 pM and 844 pM, respectively.
Example 2
In vitro evaluation of the labetalol hydrochloride and triamcinolone combination in various concentrations
Within stage two of the studies, a model was developed to test the therapeutic efficacy and interactions between the effects of labetalol hydrochloride and triamcinolone in various concentrations. The study was conducted using angioma cell lines: EOMA (ATCC® CRL-2586™) Hemangioendothelioma .
A stock solution (S2) of triamcinolone with a concentration of 1 688.5 pM was prepared. Subsequently, a stock solution (SI) of labetalol hydrochloride with a concentration of 617.8 pM was prepared. The assumption was to prepare a combination of concentrations within the IC50 values determined in cell lines for the test compounds in stage one of the studies. Table 1 below shows how combinations of concentrations were prepared to determine the best synergic action of both substances.
Table 1
Figure imgf000008_0001
Figure imgf000009_0001
51 - stock solution of labetalol hydrochloride = 617 . 8 piM
52 - stock solution of triamcinolone = 1 688 . 5 piM
Sixteen combinations of various concentrations of the test substances were obtained as shown in the diagram below .
Figure imgf000009_0002
Subsequently, the resulting 16 combinations were tested in cell lines . The average viability for all combinations was determined . In the experiment , an angioma cell line was used : EOMA (ATCC® CRL-2586™) Hemangioendothel ioma . The cells were grown in the EMEM (ATCC ) medium and seeded in a 96-well plate for 24 hours . Subsequently, they were incubated with the test compound in selected concentrations as listed in Table 1 for 48 hours . The final methanol concentration in each well was 1 pL per 100 pL of the medium . The EMEM medium with 1 pL methanol added was used as control and pure methanol was the positive control . A cytotoxicity test was performed after 48 h of incubation according to the Vybrant MTT cell proli feration test kit : 10 pL of 12 mM MTT stock solution was added to the cells and further incubated at 37 ° C for 4 h . Volume of 25 pL was removed from the wells after incubation and 50 pL DMSO was added . The plates were incubated at 37 ° C for 10 min and absorbance at 540 nm was read .
Figure imgf000010_0001
Conclusions
When the concentrations calculated based on IC50 values for the compounds were used, synergy was achieved; therefore , the ef fect of two substances used in speci fic concentrations resulted in the enhanced activity of the mixture of triamcinolone and labetalol compared to the ef fect of the drugs administered separately. It was found that labetalol hydrochloride used in the IC50 concentration in combination with small amounts of triamcinolone had an effect on the reduced viability of angioma cells. Therefore, it was shown that synergy occurred already at low corticosteroid concentrations; as a result, the dose thereof in combination with the beta-blocker could be reduced while achieving the same therapeutic effect. The use of a mixture of both test substances achieved better efficacy against angioma cancer cells than when each substance was used separately. Therefore, an effect of additive synergy was achieved.
The results of studies in angioma cells in the concentration range tested for the combination of test compounds showed that the test compounds had synergy of action for all combinations of concentrations. However, the highest synergy of action was found at labetalol hydrochloride and triamcinolone concentrations as determined for mixture no. 13.
Example 3
Preparation of pharmaceutical compositions
(a) Preparation of cream
0.5 g triamcinolone and 0.166 g labetalol hydrochloride, respectively, were weighed out, placed in a mortar and micronized. Subsequently, the weighed cream base was added and ground until a homogenous mass was obtained.
If the recipe lists a solution, micronized substances are dissolved in the solution. The weighed cream bases were ground in a mortar, and a solution containing labetalol hydrochloride and triamcinolone was gradually added. The grinding was continued until a homogenous mass was obtained. Recipe: 1 : 3 mixture (0.166 g labetalol hydrochloride ;
0.5 g triamcinolone )
3 % boric acid solution 15.0
Lekobaza to 100.0
Cream was prepared .
Recipe: 1 : 3 mixture (0.166 g labetalol hydrochloride ;
0.5 g triamcinolone )
Distilled water
Hascobaza in equal parts to 100.0
Cream was prepared .
Recipe: 1 : 3 mixture (0.166 g labetalol hydrochloride ;
0.5 g triamcinolone )
Distilled water q . s .
Lanolin 20.0
Petroleum jelly to 100.0
Cream was prepared .
Recipe: 1 : 3 mixture (0.166 g labetalol hydrochloride ;
0.5 g triamcinolone )
Eucerin
Distilled water in equal parts to 100.0
(b) Preparation of ointment
0.5 g triamcinolone and 0.166 g labetalol hydrochloride, respectively, were weighed out, placed in a mortar and micronized. Subsequently, the weighed ointment base was added and ground in the mortar until a homogenous mass was obtained.
1) Recipe: 1 : 3 mixture (0.166 g labetalol hydrochloride;
0.5 g triamcinolone)
Cholesterol ointment to 100.0
Ointment was prepared.
2) Recipe: 1 : 3 mixture (0.166 g labetalol hydrochloride;
0.5 g triamcinolone) Petroleum jelly to 100.0 Ointment was prepared.
3) Recipe: 1 : 3 mixture (0.166 g labetalol hydrochloride;
0.5 g triamcinolone) Liquid paraffin 10.0
Yellow petroleum jelly to 100.0 Ointment was prepared.
4) Recipe: 1 : 3 mixture (0.166 g labetalol hydrochloride;
0.5 g triamcinolone) Resorcinol 5.0
Liquid paraffin 5.0 Ichthyol 2.0 Zinc paste to 100.0
Ointment was prepared.
(c) Preparation of gel
0.5 g triamcinolone and 0.166 g labetalol hydrochloride, respectively, were weighed out, placed in a mortar and micronized. Subsequently, the weighed gel base was added and ground until a homogenous mass was obtained.
If the recipe lists a solution, micronized substances are dissolved in the solution. The weighed gel bases were ground in a mortar, and a solution containing labetalol hydrochloride and triamcinolone was gradually added. The grinding was continued until a homogenous mass was obtained.
1) Recipe: 1 : 3 mixture (0.166 g labetalol hydrochloride;
0.5 g triamcinolone)
2 % lignocaine gel to 50.0
Gel was prepared.
2) Recipe: 1 : 3 mixture (0.166 g labetalol hydrochloride;
0.5 g triamcinolone) Methylcellulose ointment to 100.0 Gel was prepared. 3) Recipe: 1 : 3 mixture (0.166 g labetalol hydrochloride;
0.5 g triamcinolone)
Menthol 2.0
Glycerol ointment to 50.0
Gel was prepared.
4) Recipe: 1 : 3 mixture (0.166 g labetalol hydrochloride;
0.5 g triamcinolone)
Menthol 5.0
Capsicum tincture 2.0
2 % lignocaine gel Macrogol ointment in equal parts to 100.0
Gel was prepared.
Reference list
(1) Peng Xu et al. : "A self-controlled study of intralesional injection of diprospan combined with topical timolol cream for treatment of thick superficial infantile hemangiomas"; Dermatologic Therapy 2018, 31, el2595; DOI: 10.1111/dth.12595;
(2) Alahmady H Alsmman et al. : "Combined oral propranolol with intralesional injection of triamcinolone acetonide in treatment of infantile periocular hemangiomas"; Clinical Ophthalmology 2017, 11, 2177- 2181; http://dx.doi.org/10.2147/OPTH.S153121;
(3) Wenhu Zhou et al. : "Formulation, characterization and clinical evaluation of propranolol hydrochloride gel for transdermal treatment of superficial infantile hemangioma"; Drug Development and Industrial Pharmacy 2014, Informa Healthcare USA, Inc.; DOI: 10.3109/03639045.2014.931968;
(4) Retno Danarti et al. : "Topical Timolol Maleate 0.5 % for Infantile Hemangioma: Its Effectiveness Compared to Ultrapotent Topical Corticosteroids - A SingleCenter Experience of 278 Cases"; Dermatology 2016, 232, 566-571.

Claims

Claims A pharmaceutical composition for topical application, characterized in that said composition contains a beta- adrenergic receptor antagonist, a corticosteroid and a pharmaceutically acceptable carrier, wherein the beta- adrenergic receptor antagonist is labetalol or a pharmaceutically acceptable salt thereof, and the corticosteroid is selected from a group including triamcinolone, triamcinolone acetonide, triamcinolone hexacetonide and triamcinolone diacetate. The composition of Claim 1, characterized in that the pharmaceutically acceptable salt of labetalol is the hydrochloride . The composition of Claim 1 or Claim 2, characterized in that the weight ratio of the beta-adrenergic receptor antagonist to the corticosteroid is 1 : 3. The composition of any one of Claims 1 to 3, characterized in that the concentration of the beta- adrenergic receptor antagonist in the composition is from 0.02 to 0.5 % by weight. The composition of any one of the preceding Claims 1 to
4, characterized in that the concentration of the corticosteroid in the composition is from 0.02 to 0.5 % by weight. The composition of any one of the preceding Claims 1 to
5, characterized in that said composition is in the form of cream, ointment or gel. A pharmaceutical composition as defined in Claims 1 to 6 for use in the treatment of hemangiomas in children.
PCT/PL2023/050078 2022-09-20 2023-09-20 A pharmaceutical composition for topical application and use thereof in the treatment of hemangiomas in children WO2024063661A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PLP.442316 2022-09-20
PL442316A PL244294B1 (en) 2022-09-20 2022-09-20 Pharmaceutical composition for topical use and its use in the treatment of hemangiomas in children

Publications (1)

Publication Number Publication Date
WO2024063661A1 true WO2024063661A1 (en) 2024-03-28

Family

ID=88016760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2023/050078 WO2024063661A1 (en) 2022-09-20 2023-09-20 A pharmaceutical composition for topical application and use thereof in the treatment of hemangiomas in children

Country Status (2)

Country Link
PL (1) PL244294B1 (en)
WO (1) WO2024063661A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009050567A2 (en) * 2007-10-19 2009-04-23 Université Victor Segalen-Bordeaux 2 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
WO2010118340A1 (en) * 2009-04-09 2010-10-14 University Of Medicine And Dentistry Of New Jersey Treatment of cutaneous hemangioma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009050567A2 (en) * 2007-10-19 2009-04-23 Université Victor Segalen-Bordeaux 2 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
WO2010118340A1 (en) * 2009-04-09 2010-10-14 University Of Medicine And Dentistry Of New Jersey Treatment of cutaneous hemangioma

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COUTO JAVIER A. ET AL: "Management of problematic infantile hemangioma using intralesional triamcinolone: Efficacy and safety in 100 infants", JOURNAL OF PLASTIC, RECONSTRUCTIVE AND AESTHETIC SURGERY, vol. 67, no. 11, 1 November 2014 (2014-11-01), GB, pages 1469 - 1474, XP093122445, ISSN: 1748-6815, DOI: 10.1016/j.bjps.2014.07.009 *
GARZON M C ET AL: "Ultrapotent topical corticosteroid treatment of hemangiomas of infancy", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, MOSBY, INC, US, vol. 52, no. 2, 1 February 2005 (2005-02-01), pages 281 - 286, XP004728887, ISSN: 0190-9622, DOI: 10.1016/J.JAAD.2004.09.004 *
PAINTER SALLY L ET AL: "Review of topical beta blockers as treatment for infantile hemangiomas", SURVEY OF OPHTHALMOLOGY, vol. 61, no. 1, 25 September 2015 (2015-09-25), pages 51 - 58, XP029350950, ISSN: 0039-6257, DOI: 10.1016/J.SURVOPHTHAL.2015.08.006 *
XU PENG ET AL: "A self-controlled study of intralesional injection of diprospan combined with topical timolol cream for treatment of thick superficial infantile hemangiomas", DERMATOLOGIC THERAPY, vol. 31, no. 3, 30 April 2018 (2018-04-30), US, XP093122421, ISSN: 1396-0296, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1111/dth.12595> DOI: 10.1111/dth.12595 *

Also Published As

Publication number Publication date
PL442316A1 (en) 2023-09-11
PL244294B1 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
CN108743952B (en) Phospholipid-miscible solvent-oil sustained-release drug delivery system formula of local anesthetic and preparation method thereof
TW201615221A (en) The new indication of the anti-inflammatory drugs
KR20010078754A (en) Methods and transdermal compositions for pain relief
PL207845B1 (en) Fentanyl composition for nasal administration
WO2002089794A1 (en) Method for treating neuropathic pain and pharmaceutical preparation therefor
JPH03169809A (en) Pharmaceuticals for treating acute pain and its preparation
US7674783B2 (en) Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
JP2020114862A (en) Non-aqueous patch comprising lidocaine
JP4779298B2 (en) Antitumor agent
WO2015127558A1 (en) Methods and uses for inducing or facilitating micturition in a patient in need thereof
AU2022202508A1 (en) Treatment of alopecia areata
US20210212962A1 (en) Methods and compositions for the treatment of granuloma annulare or subcutaneous inflammation and non-infection granulomatous diseases
EP1652523A1 (en) Transdermal absorption preparation
AU2018297270B2 (en) Novel treatment for hot flushes
WO2024063661A1 (en) A pharmaceutical composition for topical application and use thereof in the treatment of hemangiomas in children
RU2485956C2 (en) New composition for treating side effects of anti-cancer therapy
CN112423749A (en) Medical preparation for external use
PT95857A (en) METHOD FOR THE TREATMENT OF DEPRESSION USING PIPERAZINE DERIVATIVES
CN116265017A (en) Pharmaceutical composition comprising benvimod and corticosteroid
JP2020500915A (en) Phenytoin for local action for use in treating peripheral neuropathic pain
JP7420735B2 (en) Composition for injection
JP2009533413A (en) Pharmaceutical composition comprising an analgesic and a vitamin
EP3031448A1 (en) Nanoparticles and nanoparticle composition, and method for producing nanoparticles and nonparticle composition
RU2618462C2 (en) Method and improved pharmaceutical composition for acceleration of pde-5 inhibitor transdermal delivery
WO1998038997A1 (en) Use of levobupivacaine in combination with opiods or alfa2-agonists for providing anaesthesia or analgesia